Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer

S. C. Hopkins, I. Nissenkorn, G. M A Palmieri, M. Ikard, M. Moinuddin, M. S. Soloway

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Analysis of urinary hydroxyproline levels offers a marker to monitor osseous involvement in patients with metastatic malignancies. Such a marker is needed in patients with prostatic cancer when bone metastases predominate. Thirty-two men with stage D2 prostatic cancer were monitored by bone scan, acid and alkaline phosphatase values, and urinary hydroxyproline, beginning from 4 to 36 months after initiation of hormonal manipulation and/or systemic chemotherapy. In patients with disease progression determined by bone scan serial urinary hydroxyproline values progressively increased and were significantly elevated compared to urinary values obtained from patients with a stable or improving scan (p <0.001). Simultaneous alkaline phosphatase determinations showed less significant differences between patient groups. Acid phosphatase did not reliably indicate osseous response to therapy. These data suggest that urinary hydroxyproline values are predictive as an early objective sign of osseous response in patients receiving therapy for stage D2 prostatic cancer.

Original languageEnglish
Pages (from-to)319-323
Number of pages5
JournalJournal of Urology
Volume129
Issue number2
StatePublished - May 26 1983
Externally publishedYes

Fingerprint

Hydroxyproline
Creatinine
Prostatic Neoplasms
Acid Phosphatase
Alkaline Phosphatase
Bone and Bones
Bone Neoplasms
Disease Progression
Neoplasm Metastasis
Drug Therapy
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Hopkins, S. C., Nissenkorn, I., Palmieri, G. M. A., Ikard, M., Moinuddin, M., & Soloway, M. S. (1983). Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer. Journal of Urology, 129(2), 319-323.

Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer. / Hopkins, S. C.; Nissenkorn, I.; Palmieri, G. M A; Ikard, M.; Moinuddin, M.; Soloway, M. S.

In: Journal of Urology, Vol. 129, No. 2, 26.05.1983, p. 319-323.

Research output: Contribution to journalArticle

Hopkins, SC, Nissenkorn, I, Palmieri, GMA, Ikard, M, Moinuddin, M & Soloway, MS 1983, 'Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer', Journal of Urology, vol. 129, no. 2, pp. 319-323.
Hopkins SC, Nissenkorn I, Palmieri GMA, Ikard M, Moinuddin M, Soloway MS. Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer. Journal of Urology. 1983 May 26;129(2):319-323.
Hopkins, S. C. ; Nissenkorn, I. ; Palmieri, G. M A ; Ikard, M. ; Moinuddin, M. ; Soloway, M. S. / Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer. In: Journal of Urology. 1983 ; Vol. 129, No. 2. pp. 319-323.
@article{6c3e7d0d9be84f6b8fcd5fa5f03ab814,
title = "Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer",
abstract = "Analysis of urinary hydroxyproline levels offers a marker to monitor osseous involvement in patients with metastatic malignancies. Such a marker is needed in patients with prostatic cancer when bone metastases predominate. Thirty-two men with stage D2 prostatic cancer were monitored by bone scan, acid and alkaline phosphatase values, and urinary hydroxyproline, beginning from 4 to 36 months after initiation of hormonal manipulation and/or systemic chemotherapy. In patients with disease progression determined by bone scan serial urinary hydroxyproline values progressively increased and were significantly elevated compared to urinary values obtained from patients with a stable or improving scan (p <0.001). Simultaneous alkaline phosphatase determinations showed less significant differences between patient groups. Acid phosphatase did not reliably indicate osseous response to therapy. These data suggest that urinary hydroxyproline values are predictive as an early objective sign of osseous response in patients receiving therapy for stage D2 prostatic cancer.",
author = "Hopkins, {S. C.} and I. Nissenkorn and Palmieri, {G. M A} and M. Ikard and M. Moinuddin and Soloway, {M. S.}",
year = "1983",
month = "5",
day = "26",
language = "English",
volume = "129",
pages = "319--323",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer

AU - Hopkins, S. C.

AU - Nissenkorn, I.

AU - Palmieri, G. M A

AU - Ikard, M.

AU - Moinuddin, M.

AU - Soloway, M. S.

PY - 1983/5/26

Y1 - 1983/5/26

N2 - Analysis of urinary hydroxyproline levels offers a marker to monitor osseous involvement in patients with metastatic malignancies. Such a marker is needed in patients with prostatic cancer when bone metastases predominate. Thirty-two men with stage D2 prostatic cancer were monitored by bone scan, acid and alkaline phosphatase values, and urinary hydroxyproline, beginning from 4 to 36 months after initiation of hormonal manipulation and/or systemic chemotherapy. In patients with disease progression determined by bone scan serial urinary hydroxyproline values progressively increased and were significantly elevated compared to urinary values obtained from patients with a stable or improving scan (p <0.001). Simultaneous alkaline phosphatase determinations showed less significant differences between patient groups. Acid phosphatase did not reliably indicate osseous response to therapy. These data suggest that urinary hydroxyproline values are predictive as an early objective sign of osseous response in patients receiving therapy for stage D2 prostatic cancer.

AB - Analysis of urinary hydroxyproline levels offers a marker to monitor osseous involvement in patients with metastatic malignancies. Such a marker is needed in patients with prostatic cancer when bone metastases predominate. Thirty-two men with stage D2 prostatic cancer were monitored by bone scan, acid and alkaline phosphatase values, and urinary hydroxyproline, beginning from 4 to 36 months after initiation of hormonal manipulation and/or systemic chemotherapy. In patients with disease progression determined by bone scan serial urinary hydroxyproline values progressively increased and were significantly elevated compared to urinary values obtained from patients with a stable or improving scan (p <0.001). Simultaneous alkaline phosphatase determinations showed less significant differences between patient groups. Acid phosphatase did not reliably indicate osseous response to therapy. These data suggest that urinary hydroxyproline values are predictive as an early objective sign of osseous response in patients receiving therapy for stage D2 prostatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0020628350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020628350&partnerID=8YFLogxK

M3 - Article

C2 - 6834497

AN - SCOPUS:0020628350

VL - 129

SP - 319

EP - 323

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -